Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer.

Chinese expert consensus provides graded recommendations on perioperative immune checkpoint inhibitor use and organ-preserving strategies for locally advanced rectal cancer.

• Why it matters: With rapid growth in clinical trials and evidence, there is a need for unified standards to guide treatment decisions and improve patient outcomes in LARC.
• What they did: The consensus, based on key trial results from the past 5 years, outlines indications, medication regimens, efficacy assessments, and follow-up, emphasizing multidisciplinary decision-making and safety management.
• The result: This guidance aims to standardize perioperative immunotherapy and organ preservation approaches, supporting clinicians, patients, and policymakers in optimizing LARC treatment.